The report added that the application to withdraw the vaccine was made on March 5 and took effect on Tuesday.
The vaccine developed by AstraZeneca and Oxford University Serum Institute of India Like Covishield.
What did the company say about your departure?
The vaccine manufacturer cited commercial reasons for the withdrawal. The company voluntarily withdrew its ‘marketing authorization’ in the European Union, adding that the vaccine is no longer produced and is no longer available for use. Withdrawals have begun due to a glut of updated vaccines available.
What did AstraZeneca say in its court documents?
AstraZeneca is facing a £100 million lawsuit in the UK over admissions in court documents about rare side effects caused by its vaccine. In one of the court documents from February, AstraZeneca said its vaccine “may cause thrombosis with TTS or thrombocytopenia syndrome in very rare cases.”“.
What is thrombosis with thrombocytopenia syndrome?
Thrombosis with thrombocytopenia syndrome (TTS) is a rare but serious condition characterized by low platelet levels in the blood and the formation of blood clots. This primarily concerns certain COVID-19 vaccines, especially adenovirus vector vaccines such as the AstraZeneca and Johnson & Johnson's Janssen vaccines.
Vitamin D and Iron Supplements: Benefits and Hidden Side Effects
TTS usually appears within a few days to a few weeks after receiving the vaccine. Symptoms include severe headache, abdominal pain, leg swelling, difficulty breathing, and neurological symptoms. These symptoms may indicate that blood clots have formed in various parts of the body, including the brain, abdomen, and lungs.
The exact cause of TTS is not fully known, but it is believed to be related to an immune response triggered by a vaccine, leading to abnormal clotting and platelet destruction. Diagnosis requires clinical evaluation, imaging studies to detect blood clots, and laboratory tests to check for low platelet counts.
Treatment for TTS often involves hospitalization and specialized treatment, including anticoagulant therapy to prevent further clots from forming and intravenous immunoglobulin to stabilize platelet counts. Prompt recognition and management are essential to prevent serious complications, including organ damage or death, associated with TTS.